PURPOSE: Small cell lung cancer (SCLC) is a highly aggressive tumor, and few studies have examined the amplification status of the MYC gene in tumor samples using chromogenic in situ hybridization (CISH). Emerging target treatments associated with MYC status in SCLC necessitates the evaluation of MYC using current methodologies, such as CISH. In this study, we evaluated tissue samples from untreated patients to determine the relation between MYC amplification and clinical and pathological factors, including survival. METHODS: Formalin-fixed paraffin-embedded tumor samples were obtained from 77 patients with SCLC who underwent a diagnostic biopsy for SCLC. The samples were analyzed by CISH using a MYC probe (ZytoDot(®) CISH probe). The relationship between cytogenetic analysis, pathologic characteristics and survival time was evaluated using the Chi-square test, Fisher's test and Mann-Whitney method. A regression model was constructed to exclude any confounding factors. RESULTS: Of 77 samples, 64.9 % were from bronchi biopsy and the remainder was from the mediastinal, cervical and supraclavicular lymph nodes. The MYC oncogene was amplified in 20 % of the tumors. After the multivariate regression analysis, patients with MYC amplification had a significantly shorter survival time (4.67 weeks) versus patients without MYC amplification (26.15 weeks) (p = 0.02, CI 1.355-10.261). CONCLUSION: MYC amplification is a frequent event in SCLC and is related to a short survival time. MYC amplification may be an independent prognostic factor for SCLC. Further studies are required to support this finding and clarify the role of MYC in SCLC tumorigenesis.
PURPOSE:Small cell lung cancer (SCLC) is a highly aggressive tumor, and few studies have examined the amplification status of the MYC gene in tumor samples using chromogenic in situ hybridization (CISH). Emerging target treatments associated with MYC status in SCLC necessitates the evaluation of MYC using current methodologies, such as CISH. In this study, we evaluated tissue samples from untreated patients to determine the relation between MYC amplification and clinical and pathological factors, including survival. METHODS:Formalin-fixed paraffin-embedded tumor samples were obtained from 77 patients with SCLC who underwent a diagnostic biopsy for SCLC. The samples were analyzed by CISH using a MYC probe (ZytoDot(®) CISH probe). The relationship between cytogenetic analysis, pathologic characteristics and survival time was evaluated using the Chi-square test, Fisher's test and Mann-Whitney method. A regression model was constructed to exclude any confounding factors. RESULTS: Of 77 samples, 64.9 % were from bronchi biopsy and the remainder was from the mediastinal, cervical and supraclavicular lymph nodes. The MYC oncogene was amplified in 20 % of the tumors. After the multivariate regression analysis, patients with MYC amplification had a significantly shorter survival time (4.67 weeks) versus patients without MYC amplification (26.15 weeks) (p = 0.02, CI 1.355-10.261). CONCLUSION:MYC amplification is a frequent event in SCLC and is related to a short survival time. MYC amplification may be an independent prognostic factor for SCLC. Further studies are required to support this finding and clarify the role of MYC in SCLC tumorigenesis.
Authors: B E Johnson; D C Ihde; R W Makuch; A F Gazdar; D N Carney; H Oie; E Russell; M M Nau; J D Minna Journal: J Clin Invest Date: 1987-06 Impact factor: 14.808
Authors: H Kubokura; T Tenjin; H Akiyama; K Koizumi; H Nishimura; M Yamamoto; S Tanaka Journal: Ann Thorac Cardiovasc Surg Date: 2001-08 Impact factor: 1.520
Authors: T Takahashi; Y Obata; Y Sekido; T Hida; R Ueda; H Watanabe; Y Ariyoshi; T Sugiura; T Takahashi Journal: Cancer Res Date: 1989-05-15 Impact factor: 12.701
Authors: M M Nau; B J Brooks; D N Carney; A F Gazdar; J F Battey; E A Sausville; J D Minna Journal: Proc Natl Acad Sci U S A Date: 1986-02 Impact factor: 11.205
Authors: Barbara A Helfrich; Jihye Kim; Dexiang Gao; Daniel C Chan; Zhiyong Zhang; Aik-Choon Tan; Paul A Bunn Journal: Mol Cancer Ther Date: 2016-08-05 Impact factor: 6.261
Authors: Marcela S Cavalcanti; Anne M Schultheis; Caleb Ho; Lu Wang; Deborah F DeLair; Britta Weigelt; Ginger Gardner; Stuart M Lichtman; Meera Hameed; Kay J Park Journal: Int J Gynecol Pathol Date: 2017-01 Impact factor: 2.762
Authors: Kathryn L Simpson; Ruth Stoney; Kristopher K Frese; Nicole Simms; William Rowe; Simon P Pearce; Sam Humphrey; Laura Booth; Derrick Morgan; Marek Dynowski; Francesca Trapani; Alessia Catozzi; Mitchell Revill; Thomas Helps; Melanie Galvin; Luc Girard; Daisuke Nonaka; Louise Carter; Matthew G Krebs; Natalie Cook; Mathew Carter; Lynsey Priest; Alastair Kerr; Adi F Gazdar; Fiona Blackhall; Caroline Dive Journal: Nat Cancer Date: 2020-04-13
Authors: Jiannong Li; Bin Fang; Fumi Kinose; Yun Bai; Jae-Young Kim; Yian A Chen; Uwe Rix; John M Koomen; Eric B Haura Journal: Mol Cancer Ther Date: 2016-01-15 Impact factor: 6.261
Authors: Lisa Maria Mustachio; Jason Roszik; Aimee T Farria; Karla Guerra; Sharon Yr Dent Journal: Am J Cancer Res Date: 2019-08-01 Impact factor: 6.166
Authors: Wei Zhang; Luc Girard; Yu-An Zhang; Tomohiro Haruki; Mahboubeh Papari-Zareei; Victor Stastny; Hans K Ghayee; Karel Pacak; Trudy G Oliver; John D Minna; Adi F Gazdar Journal: Transl Lung Cancer Res Date: 2018-02
Authors: Xuan Yang; Dacheng Fan; Aidan Henry Troha; Hyunjun Max Ahn; Kun Qian; Bo Liang; Yuhong Du; Haian Fu; Andrey A Ivanov Journal: Bioorg Med Chem Date: 2021-07-22 Impact factor: 3.461